PDF herunterladen
Semin Thromb Hemost 2014; 40(03): 338-347
DOI: 10.1055/s-0034-1370793
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Venous Thromboembolism in Multiple Myeloma

Valerio De Stefano
1   Institute of Hematology, Department of Medical Sciences, Catholic University, Rome, Italy
,
Tommaso Za
1   Institute of Hematology, Department of Medical Sciences, Catholic University, Rome, Italy
,
Elena Rossi
1   Institute of Hematology, Department of Medical Sciences, Catholic University, Rome, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
05. März 2014 (online)

    Lizenzen und Reprints

Abstract

As for other malignancies, multiple myeloma is associated with an increased risk of venous thromboembolism (VTE). The incidence of VTE is estimated as 8 to 22 per 1,000 person-years; risk factors can be patient related (advanced age, other risk factors shared with the general population), disease related, and treatment related. Disease-related risk factors can derive from the monoclonal component (rarely hyperviscosity or inhibition of natural anticoagulants) or hypercoagulability sustained by inflammatory cytokines (increased von Willebrand factor, factor VIII, fibrinogen levels, decreased protein S levels, acquired activated protein C resistance). The 1 to 2% baseline of incident VTE associated with conventional therapies as melphalan and prednisone is at least doubled by the use of doxorubicin or other chemotherapeutic agents. The VTE rate associated with thalidomide or lenalidomide as monotherapy is similar, whereas combination with high-dose dexamethasone or multiple chemotherapeutic agents induces a multiplicative effect on the VTE rate up to 25%. Low-molecular-weight heparin (LMWH), fixed low-dose warfarin, and aspirin are acceptable strategies for antithrombotic prophylaxis, reducing VTE to 5 to 8% in thalidomide-treated patients and 1 to 3% in lenalidomide-treated patients. LMWH shows an advantage in efficacy not statistically significant. Prophylaxis should be tailored considering individual risk factors for VTE, the stage of disease, the possible occurrence of thrombocytopenia, or renal insufficiency.

Keywords

multiple myeloma - venous thromboembolism - thalidomide - lenalidomide - antithrombotic prophylaxis
 

  • References

  • 1 Cushman M, Tsai AW, White RH , et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117 (1) 19-25
    CrossrefPubMedGoogle Scholar
  • 2 Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232 (2) 155-160
    CrossrefPubMedGoogle Scholar
  • 3 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83 (5) 657-660
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (4) 692-699
    CrossrefPubMedGoogle Scholar
  • 5 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160 (6) 809-815
    CrossrefPubMedGoogle Scholar
  • 6 Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160 (22) 3415-3420
    CrossrefPubMedGoogle Scholar
  • 7 Ocak G, Vossen CY, Verduijn M , et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost 2013; 11 (1) 116-123
    CrossrefPubMedGoogle Scholar
  • 8 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 (6) 715-722
    CrossrefPubMedGoogle Scholar
  • 9 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127 (12) 2893-2917
    CrossrefPubMedGoogle Scholar
  • 10 Surveillance Epidemiology and End Results SEER 2006–2010. Available at: http://www.seer.cancer.gov/statfacts/html/mulmy.htlm . Accessed October 9, 2013
    PubMedGoogle Scholar
  • 11 Kristinsson SY, Fears TR, Gridley G , et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008; 112 (9) 3582-3586
    CrossrefPubMedGoogle Scholar
  • 12 Kristinsson SY, Pfeiffer RM, Björkholm M , et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010; 115 (24) 4991-4998
    CrossrefPubMedGoogle Scholar
  • 13 Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4 (3) 529-535
    CrossrefPubMedGoogle Scholar
  • 14 Cronin-Fenton DP, Søndergaard F, Pedersen LA , et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103 (7) 947-953
    CrossrefPubMedGoogle Scholar
  • 15 Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis 2009; 20 (5) 337-339
    CrossrefPubMedGoogle Scholar
  • 16 Cini M, Zamagni E, Valdré L , et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol 2010; 84 (6) 484-492
    CrossrefPubMedGoogle Scholar
  • 17 De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87 (10) 1095-1108
    PubMedGoogle Scholar
  • 18 Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134 (4) 399-405
    CrossrefPubMedGoogle Scholar
  • 19 Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15 (10) 1490-1494
    CrossrefPubMedGoogle Scholar
  • 20 Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101 (3) 558-566
    CrossrefPubMedGoogle Scholar
  • 21 Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance. Clin Adv Hematol Oncol 2009; 7 (12) 827-832
    PubMedGoogle Scholar
  • 22 Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch Intern Med 1997; 157 (15) 1665-1670
    CrossrefPubMedGoogle Scholar
  • 23 Cohen AL, Sarid R. The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. Thromb Res 2010; 125 (3) 216-219
    CrossrefPubMedGoogle Scholar
  • 24 Gregersen H, Nørgaard M, Severinsen MT, Engebjerg MC, Jensen P, Sørensen HT. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol 2011; 86 (2) 129-134
    CrossrefPubMedGoogle Scholar
  • 25 Za T, De Stefano V, Rossi E , et al; Multiple Myeloma GIMEMA-Latium Region Working Group. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. Br J Haematol 2013; 160 (5) 673-679
    CrossrefPubMedGoogle Scholar
  • 26 Uaprasert N, Voorhees PM, Mackman N, Key NS. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. Eur J Cancer 2010; 46 (10) 1790-1799
    CrossrefPubMedGoogle Scholar
  • 27 Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 2003; 29 (5) 467-471
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 28 Kwaan HC. Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc 2013; 55 (1) 75-83
    PubMedGoogle Scholar
  • 29 Gabriel DA, Smith LA, Folds JD, Davis L, Cancelosi SE. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med 1983; 101 (4) 545-552
    PubMedGoogle Scholar
  • 30 Carr Jr ME, Zekert SL. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma. Am J Physiol 1994; 266 (3 Pt 2) H1195-H1201
    PubMedGoogle Scholar
  • 31 Carr Jr ME, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 1996; 128 (1) 83-88
    CrossrefPubMedGoogle Scholar
  • 32 Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 2008; 6 (3) 161-180
    CrossrefPubMedGoogle Scholar
  • 33 Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009; 145 (2) 151-163
    CrossrefPubMedGoogle Scholar
  • 34 Federici AB, Rand JH, Bucciarelli P , et al; Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84 (2) 345-349
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 35 Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol 1999; 62 (2) 99-102
    CrossrefPubMedGoogle Scholar
  • 36 Gruber A, Blaskó G, Sas G. Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res 1986; 42 (4) 579-581
    CrossrefPubMedGoogle Scholar
  • 37 Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am J Hematol 1996; 51 (4) 319-323
    CrossrefPubMedGoogle Scholar
  • 38 Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 2011; 37 (3) 209-219
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 39 Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev 2010; 24 (Suppl. 01) S5-S11
    CrossrefPubMedGoogle Scholar
  • 40 Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001; 115 (1) 3-12
    CrossrefPubMedGoogle Scholar
  • 41 Joseph L, Fink LM, Hauer-Jensen M. Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood Coagul Fibrinolysis 2002; 13 (2) 105-116
    CrossrefPubMedGoogle Scholar
  • 42 Gomperts ED, Shulman G, Lynch SR. Factor VIII and factor-VIII-related antigen in multiple myelomatosis and related conditions. Br J Haematol 1976; 32 (2) 249-255
    CrossrefPubMedGoogle Scholar
  • 43 Leone G, Valori VM, Zini G, Bavaro P, Bartoloni C, Bizzi B. Factor VIII complex in myelomatosis and related disorders. Ric Clin Lab 1982; 12 (4) 581-588
    PubMedGoogle Scholar
  • 44 Petropoulou AD, Gerotziafas GT, Samama MM, Hatmi M, Rendu F, Elalamy I. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thromb Res 2008; 121 (4) 493-497
    CrossrefPubMedGoogle Scholar
  • 45 van Marion AM, Auwerda JJ, Lisman T , et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008; 32 (7) 1078-1084
    CrossrefPubMedGoogle Scholar
  • 46 Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92 (2) 279-280
    CrossrefPubMedGoogle Scholar
  • 47 Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost 2008; 99 (6) 1040-1048
    PubMedGoogle Scholar
  • 48 Auwerda JJ, Yuana Y, Osanto S , et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105 (1) 14-20
    PubMedGoogle Scholar
  • 49 Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1 (3) 445-449
    CrossrefPubMedGoogle Scholar
  • 50 Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 2010; 116 (1) 22-26
    CrossrefPubMedGoogle Scholar
  • 51 Zangari M, Saghafifar F, Anaissie E , et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13 (3) 187-192
    CrossrefPubMedGoogle Scholar
  • 52 Deitcher SR, Choueiri T, Srkalovic G, Hussein MA. Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. Br J Haematol 2003; 123 (5) 959
    CrossrefPubMedGoogle Scholar
  • 53 Zangari M, Berno T, Zhan F, Boucher KM, Tricot G, Fink L. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagul Fibrinolysis 2011; 22 (5) 420-423
    CrossrefPubMedGoogle Scholar
  • 54 Yağci M, Sucak GT, Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol 2003; 74 (4) 231-237
    CrossrefPubMedGoogle Scholar
  • 55 van Marion AM, Auwerda JJ, Minnema MC , et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 2005; 94 (6) 1341-1343
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 56 Cortelezzi A, Moia M, Falanga A , et al; CATHEM Study Group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005; 129 (6) 811-817
    CrossrefPubMedGoogle Scholar
  • 57 Kumar SK, Dispenzieri A, Lacy MQ , et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2013; (e-pub ahead of print). doi:10.1038/leu.2013.313
    PubMedGoogle Scholar
  • 58 Barlogie B, Jagannath S, Desikan KR , et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93 (1) 55-65
    PubMedGoogle Scholar
  • 59 Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 2009; 123 (5) 679-686
    CrossrefPubMedGoogle Scholar
  • 60 Bennett CL, Angelotta C, Yarnold PR , et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006; 296 (21) 2558-2560
    PubMedGoogle Scholar
  • 61 Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR ; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24 (3) 431-436
    CrossrefPubMedGoogle Scholar
  • 62 Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9 (4) 653-663
    CrossrefPubMedGoogle Scholar
  • 63 Zangari M, Anaissie E, Barlogie B , et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98 (5) 1614-1615
    CrossrefPubMedGoogle Scholar
  • 64 Zangari M, Siegel E, Barlogie B , et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100 (4) 1168-1171
    CrossrefPubMedGoogle Scholar
  • 65 Palumbo A, Bringhen S, Caravita T , et al; Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367 (9513) 825-831
    CrossrefPubMedGoogle Scholar
  • 66 Hicks LK, Haynes AE, Reece DE , et al; Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008; 34 (5) 442-452
    CrossrefPubMedGoogle Scholar
  • 67 Rajkumar SV, Jacobus S, Callander NS , et al; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11 (1) 29-37
    CrossrefPubMedGoogle Scholar
  • 68 Zonder JA, Crowley J, Hussein MA , et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010; 116 (26) 5838-5841
    CrossrefPubMedGoogle Scholar
  • 69 Attal M, Lauwers-Cances V, Marit G , et al; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366 (19) 1782-1791
    CrossrefPubMedGoogle Scholar
  • 70 Fouquet G, Tardy S, Demarquette H , et al. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer 2013; 119 (20) 3680-3686
    PubMedGoogle Scholar
  • 71 Knop S, Gerecke C, Liebisch P , et al. Lenalidomide, Adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113 (18) 4137-4143
    CrossrefPubMedGoogle Scholar
  • 72 Palumbo A, Hajek R, Delforge M , et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366 (19) 1759-1769
    CrossrefPubMedGoogle Scholar
  • 73 Schey SA, Fields P, Bartlett JB , et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22 (16) 3269-3276
    CrossrefPubMedGoogle Scholar
  • 74 Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008; 141 (1) 41-51
    CrossrefPubMedGoogle Scholar
  • 75 Lacy MQ, Hayman SR, Gertz MA , et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24 (11) 1934-1939
    CrossrefPubMedGoogle Scholar
  • 76 Lacy MQ, Allred JB, Gertz MA , et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011; 118 (11) 2970-2975
    CrossrefPubMedGoogle Scholar
  • 77 Richardson PG, Siegel D, Baz R , et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013; 121 (11) 1961-1967
    CrossrefPubMedGoogle Scholar
  • 78 Miguel JS, Weisel K, Moreau P , et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14 (11) 1055-1066
    CrossrefPubMedGoogle Scholar
  • 79 Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk 2011; 11 (2) 228-236
    CrossrefPubMedGoogle Scholar
  • 80 Lonial S, Richardson PG, San Miguel J , et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008; 143 (2) 222-229
    CrossrefPubMedGoogle Scholar
  • 81 Fusté B, Serradell M, Escolar G , et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88 (4) 678-685
    PubMedGoogle Scholar
  • 82 Tobu M, Iqbal O, Fareed D , et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004; 10 (3) 225-232
    CrossrefPubMedGoogle Scholar
  • 83 Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354 (19) 2079-2080
    CrossrefPubMedGoogle Scholar
  • 84 Galli M, Elice F, Crippa C, Comotti B, Rodeghiero F, Barbui T. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 2004; 89 (9) 1141-1142
    PubMedGoogle Scholar
  • 85 Anaissie EJ, Coleman EA, Goodwin JA , et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer 2012; 118 (2) 549-557
    CrossrefPubMedGoogle Scholar
  • 86 Leleu X, Rodon P, Hulin C , et al. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost 2013; 110 (4) 844-851
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 87 Cavo M, Zamagni E, Tosi P , et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89 (7) 826-831
    PubMedGoogle Scholar
  • 88 Zangari M, Barlogie B, Anaissie E , et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126 (5) 715-721
    CrossrefPubMedGoogle Scholar
  • 89 Minnema MC, Breitkreutz I, Auwerda JJ , et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18 (12) 2044-2046
    CrossrefPubMedGoogle Scholar
  • 90 Klein U, Kosely F, Hillengass J , et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009; 88 (1) 67-71
    CrossrefPubMedGoogle Scholar
  • 91 Baz R, Li L, Kottke-Marchant K , et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80 (12) 1568-1574
    CrossrefPubMedGoogle Scholar
  • 92 Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M ; Italian Multiple Myeloma Network, Gimema. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006; 4 (8) 1842-1845
    CrossrefPubMedGoogle Scholar
  • 93 Dunkley S, Gaudry L. Thalidomide causes platelet activation, which can be abrogated by aspirin. J Thromb Haemost 2007; 5 (6) 1323-1325
    CrossrefPubMedGoogle Scholar
  • 94 Robak M, Treliński J, Chojnowski K. Hemostatic changes after 1.  month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol 2012; 29 (5) 3574-3580
    CrossrefPubMedGoogle Scholar
  • 95 Abdullah WZ, Roshan TM, Hussin A, Zain WS, Abdullah D. Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. Blood Coagul Fibrinolysis 2013; 24 (8) 893-895
    CrossrefPubMedGoogle Scholar
  • 96 Palumbo A, Cavo M, Bringhen S , et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29 (8) 986-993
    CrossrefPubMedGoogle Scholar
  • 97 Larocca A, Cavallo F, Bringhen S , et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119 (4) 933-939 , quiz 1093
    CrossrefPubMedGoogle Scholar
  • 98 Palumbo A, Rajkumar SV, Dimopoulos MA , et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22 (2) 414-423
    CrossrefPubMedGoogle Scholar
  • 99 Kristinsson SY. Thrombosis in multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 437-444
    CrossrefPubMedGoogle Scholar
  • 100 Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood 2013; 122 (14) 2310-2317
    CrossrefPubMedGoogle Scholar